ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a privately-held, clinical-stage biotechnology company, announced today that Chief Executive Officer Sean Ainsworth will present at the 27th Annual Piper Jaffray Healthcare Conference and the Genetic RX Conference. RetroSense Therapeutics is at the forefront of developing optogenetic therapies for vision restoration. Patient recruitment is currently underway for a clinical trial investigating lead product, RST-001, for the treatment of retinitis pigmentosa, a genetic disease characterized by deteriorating vision and blindness.
27th Piper Jaffray Annual Healthcare Conference
Ainsworth is scheduled to participate in a panel discussion, “Gene Therapy for Ophthalmology – Eye On The Prize” at the 27th Annual Piper Jaffray Healthcare Conference taking place at The New York Palace Hotel in New York on Tuesday, December 1st at 10:00 a.m. EST.
Genetic RX Conference
Ainsworth is also scheduled to participate in a panel discussion, “A Future of One-Time Cures: Business Development and Pricing Considerations” at the Genetic RX Conference taking place at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, on Thursday, December 3rd at 9:10 a.m. EST.
About RetroSense Therapeutics
RetroSense Therapeutics is a privately-held, clinical-stage biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through clinical trials. For more information about RetroSense Therapeutics, visit http://www.retro-sense.com/.